Market Strategy 12/21/2020
- December 21, 2020
How High the Moon?
With equity markets posting new record highs just last week investors ask a question that recalls the title of a jazz standard
- As we went to press on Sunday night, news crossed the transom that Congressional leaders reached a deal on a roughly $900 billion economic rescue package for the US economy. The agreement augurs well for the economic outlook and for equity market performance in a holiday-abridged week.
- The news of the approval of a second vaccine and its launch this week In the US is likely to further improve sentiment in the markets this week.
- The recent weakening of the US dollar has substantially improved returns for US investors in foreign stocks. Prospects for a global economic recovery in a post-Covid environment could further enhance returns going forward.
The US equity markets as a discount mechanism (pricing the value of stocks in the future) have pushed major stock indices higher on a year to date basis than many investors and observers would have thought possible in March of this year when Covid-19 became broadly recognized as a pandemic by government officials in the US and around the world marking the start of shutdowns across large segments of the world economy.
But here we are some nine months later with the launch of the first vaccine approved stateside last Monday, another approved over the weekend to be launched this week with more to follow over the next few months. According to the Centers for Disease Control and Prevention (via Bloomberg) so far 556,208 doses of vaccine have been administered in the US. Some countries outside of the US were already in process of inoculating segments of their population and more are expected to join the process over the course of the next few weeks and months. As awful as the pandemic has been in terms of lives lost, illness endured, as well as its costly disruption of the US and world economies its overall effect has touched so many people that a level of broader acceptance and inoculation may very well be achieved than had been earlier projected by health authorities. Wide acceptance and usage of the vaccines could well help accelerate and propel the economic recovery that is likely to follow and has begun to be priced into equities in bourses around the world.
As always it remains important for investors to keep things in perspective, right size expectations, practice diversification and patience and know what you own and why you own it and hold reasonable expectations of how those investments you own will perform as the US and world economies transition towards “The Next Normal”.
Advancements in technology, biotechnology, pharmacology, diagnostics and equipment have enabled the start of this process at what the current administration in Washington has coined “warp speed” in comparison to vaccines developed to stem the spread of other viruses in prior centuries and decades when vaccines of great efficacy could take decades for medical research to arrive at.
Two medical professionals in private practice that we spoke with just last week attributed technological advances achieved in the past few years for a process that has been able to deliver a vaccine capable of stemming the spread of Covid -19 in such a short time span— in a period of months rather than what has been the norm—years even decades.
Such progress in medicine has helped boost investor sentiment and expectations with some consideration to what effect the vaccine(s) may have in accelerating and securing the process of reopening the stateside economy, and generating economic growth that could revive segments of the economy (particularly in services and leisure including hotels, airlines, entertainment and office buildings among others) that have yet to recover from the pandemic’s wrath.
Monetary policy by the Federal Reserve which remains consistently supportive of a challenged economy along with the next round of fiscal stimulus tentatively agreed on by Congressional leaders broadly supports equity prices at these levels and also suggests that there is further upside ahead notwithstanding the emergence of catalysts that could appear intermittently to cause short-term nervous investors, bears and skeptics to take some profits intermittently.
As stocks have rebounded this year since the low on March 23rd and pushed higher through the fourth quarter this year many investors wonder how long stocks can stay on track in an upward trajectory leading toward what has been coined by some as “the next normal.”
Their question reminds us of the title of a classic jazz tune from the early 1940s titled, “How High the Moon?”
We reply that trees and stocks don’t rise to reach the sky but in bull markets and in bull runs often appear intentioned to do so. The bull market that rose like a phoenix from the low on March 23rd of this year similar to its predecessor (the bull market that emerged from the Great Financial Crisis low of March 9, 2009) is broad in scope and global.
While there are segments of the markets (including “story stocks,” some IPOs, and cyber currencies) that exhibit levels of animal spirits and speculation, a process of rotation and rebalancing points to a wide selection of stocks that trade at more sensible valuations while still offering significant opportunities for investors. A broadening of investor appetite not just for growth but for value stocks as well as a resilience in equity prices and improved revenue and earnings trends suggest to us that this bull market has further to run.
As always it remains important for investors to keep things in perspective, right size expectations, practice diversification and patience and know what you own and why you own it and hold reasonable expectations of how those investments you own will perform as the US and world economies transition towards “The Next Normal.”
Chief Investment Strategist, Oppenheimer Asset Management Inc.
John is one of the most popular faces around Oppenheimer: our clients have come to rely on his market recaps for timely analysis and a confident viewpoint on the road forward. He frequently lends his expertise to CNBC, Bloomberg, Fox Business, and other notable networks.
Additional Market Insights
This report is issued and approved by Oppenheimer & Co. Inc., a member of all Principal Exchanges, and SIPC. This report is distributed by Oppenheimer & Co. Inc., for informational purposes only, to its institutional and retail investor clients. This report does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. The securities mentioned in this report may not be suitable for all types of investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer & Co. Inc. Recipients should consider this report as only a single factor in making an investment decision and should not rely solely on investment recommendations contained herein, if any, as a substitution for the exercise of independent judgment of the merits and risks of investments. The strategist writing this report is not a person or company with actual, implied or apparent authority to act on behalf of any issuer mentioned in the report. Before making an investment decision with respect to any security discussed in this report, the recipient should consider whether such investment is appropriate given the recipient's particular investment needs, objectives and financial circumstances. We recommend that investors independently evaluate particular investments and strategies, and encourage investors to seek the advice of a financial advisor. Oppenheimer & Co. Inc. will not treat non-client recipients as its clients solely by virtue of their receiving this report. Past performance is not a guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance of any security mentioned in this report. The price of the securities mentioned in this report and the income they produce may fluctuate and/or be adversely affected by exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal.
Oppenheimer & Co. Inc. accepts no liability for any loss arising from the use of information contained in this report. All information, opinions and statistical data contained in this report were obtained or derived from public sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such information, opinion or statistical data is accurate or complete and they should not be relied upon as such. All estimates and opinions expressed herein constitute judgments as of the date of this report and are subject to change without notice. Nothing in this report constitutes legal, accounting or tax advice. Since the levels and bases of taxation can change, any reference in this report to the impact of taxation.
Investment Strategy should not be construed as offering tax advice on the tax consequences of investments. As with any investment having potential tax implications, clients should consult with their own independent tax adviser.
This report may provide addresses of, or contain hyperlinks to, Internet web sites. Oppenheimer & Co. Inc. has not reviewed the linked Internet web site of any third party and takes no responsibility for the contents thereof. Each such address or hyperlink is provided solely for the recipient's convenience and information, and the content of linked third party web sites is not in any way incorporated into this document. Recipients who choose to access such third-party web sites or follow such hyperlinks do so at their own risk. The S&P 500 Index is an unmanaged value-weighted index of 500 common stocks that is generally considered representative of the U.S. stock market. The S&P 500 index figures do not reflect any fees, expenses or taxes. This research is distributed in the UK and elsewhere throughout Europe, as third party research by Oppenheimer Europe Ltd, which is authorized and regulated by the Financial Conduct Authority (FCA). This research is for information purposes only and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This report is for distribution only to persons who are eligible counterparties or professional clients and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the UK only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) High Net Worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. In particular, this material is not for distribution to, and should not be relied upon by, retail clients, as defined under the rules of the FCA. Neither the FCA’s protection rules nor compensation scheme may be applied. This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Oppenheimer & Co. Inc. Copyright © Oppenheimer & Co. Inc. 2020.